Suppressing APOE4-induced neural pathologies by targeting the VHL–HIF axis

W Wei I. Jiang (Cardiovascular Research Institute, University of California San Francisco) Y Yiming Cao (Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Y Yue Xue (Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) Y Yichun Ji (Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University) B Benjamin Y. Winer (Cardiovascular Research Institute, University of California San Francisco) R Rashmi Chandra (Cardiovascular Research Institute, University of California San Francisco) X Xingyuan Fischer Zhang (Cardiovascular Research Institute, University of California San Francisco) M Mengqi Zhang N Neel S. Singhal (Department of Neurology, University of California San Francisco) J Jonathan T. Pierce (Department of Neuroscience, The Center for Learning and Memory, Waggoner Center for Alcohol and Addiction Research, Institute of Neuroscience, University of Texas at Austin) S Song Chen (Department of Applied Physics, School of Medical Imaging) D Dengke K. Ma (Cardiovascular Research Institute, University of California San Francisco)

Abstract

The ε4 variant of human apolipoprotein E ( APOE4 ) is a key genetic risk factor for neurodegeneration in Alzheimer’s disease and elevated all-cause mortality in humans. Understanding the factors and mechanisms that can mitigate the harmful effects of APOE4 has significant implications. In this study, we find that inactivating the VHL-1 (Von Hippel–Lindau) protein can suppress mortality, neural and behavioral pathologies caused by transgenic human APOE4 in Caenorhabditis elegans . The protective effects of VHL-1 deletion are recapitulated by stabilized HIF-1 (hypoxia-inducible factor), a transcription factor degraded by VHL-1. HIF-1 activates a genetic program that safeguards against mitochondrial dysfunction, oxidative stress, proteostasis imbalance, and endolysosomal rupture—critical cellular events linked to neural pathologies and mortality. Furthermore, genetic inhibition of Vhl reduces cerebral vascular injury and synaptic lesions in APOE4 mice, suggesting an evolutionarily conserved mechanism. Thus, we identify the VHL–HIF axis as a potent modulator of APOE4 -induced neural pathologies and propose that targeting this pathway in nonproliferative tissues may curb cellular damage, protect against neurodegeneration, and reduce tissue injuries and mortality.

Article Details

Volume / Issue Vol. 122, Issue 5
Published February 04, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

W

Wei I. Jiang

Cardiovascular Research Institute, University of California San Francisco

Y

Yiming Cao

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University

Y

Yue Xue

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University

Y

Yichun Ji

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University

B

Benjamin Y. Winer

Cardiovascular Research Institute, University of California San Francisco

R

Rashmi Chandra

Cardiovascular Research Institute, University of California San Francisco

X

Xingyuan Fischer Zhang

Cardiovascular Research Institute, University of California San Francisco

M

Mengqi Zhang

N

Neel S. Singhal

Department of Neurology, University of California San Francisco

J

Jonathan T. Pierce

Department of Neuroscience, The Center for Learning and Memory, Waggoner Center for Alcohol and Addiction Research, Institute of Neuroscience, University of Texas at Austin

S

Song Chen

Department of Applied Physics, School of Medical Imaging

D

Dengke K. Ma

Cardiovascular Research Institute, University of California San Francisco